Table 4 Response, remission, recovery, and study discontinuation
| Â | Placebo | Olanzapine | p Value |
|---|---|---|---|
|  | (n = 52) | (n = 104) |  |
| Â | n (%) | n (%) | Â |
Response | 21 (40.4) | 57 (54.8) | .13 |
Partial remission (MADRS ≤12) | 29 (55.8) | 56 (53.8) | .87 |
Full remission (MADRS ≤8) | 18 (34.6) | 45 (43.3) | .39 |
Recovery | 5 (9.6) | 15 (14.4) | .46 |
Study discontinuations | Â | Â | Â |
 Total | 11 (21.2) | 18 (17.3) | .66 |
 Due to adverse events | 4 (7.7) | 10 (9.6) | .78 |
 Due to lack of efficacy | 1 (1.9) | 0 (0.0) | .33 |
 Lost to follow-up | 0 (0.0) | 1 (1.0) | 1.00 |